Does Alkermes plc. have an economic moat?

Based on its FY2025 SEC filings, the Moat Index scores Alkermes plc. (ALKS) 52.3 out of 100 — a Shallow moat. The five questions behind that score begin at 20% each; if exactly one genuinely lacks data, the other four weights are renormalized and disclosed. revenue and EPS trend 52, pricing power 100, returns on capital 11, balance-sheet safety 73, capital allocation 27.

Is ALKS trading below the conservative owner-earnings estimate?

The value if growth stopped today — a zero-growth baseline — is $16.21 per share. It capitalizes normalized owner earnings at a 9% rate and assumes 0% growth. Versus a recent price of $40.10, that is 147% above value if growth stopped today. The model also publishes a capped-growth comparison, but the zero-growth estimate is the cautious baseline. It assumes trailing owner earnings persist and is unreliable for declining businesses. This is an educational estimate from primary SEC filings, not intrinsic value as a fact or investment advice.

How has ALKS's Moat Score changed over time?

The record logs 29 readings since Jul 17, 2026; the latest reads 52.3 out of 100 (shallow moat). No tier changes on record yet. (Methodology or normalizer upgrades on Jul 20, 2026, Jul 23, 2026, Jul 26, 2026 re-based the score; readings across versions aren't compared.) The history is append-only — readings are only ever added, never rewritten.

Alkermes plc.

ALKS · Healthcare · $6.6B mkt cap · FY2025 filings · as of Oct 16, 2026 · Shallow moat ·

Doesn't clear the bar

Shallow moat

The five investor questions

2021–2025 (latest 5 aligned FYs; v3 window cap 5): revenue $1.2B to $1.5B, increasing; diluted EPS -0.29 to 1.43, increasing.

100

Median gross margin 83.5% over 10y, very stable.

Median ROIC -3.5%, above the 12% hurdle in 30% of years.

Net debt/EBITDA n/ax, interest coverage 21x.

Owner earnings changed trend unclear over up to the ten most recent annual observations.

Price vs. value if growth stopped today

A cautious baseline, not a price target: what the shares may support if normalized owner earnings simply hold steady.

Above value if growth stopped todayBelow value if growth stopped today

147% above value if growth stopped today

: $242M
: $16.21
: $16.21
: $40.10
: 147% above value if growth stopped today

What today’s price assumes: owner earnings growing ~20%/yr over 5 years. The zero-growth estimate assumes owner earnings stay flat (0% growth).

How to read this

We solve for the constant annual change in owner earnings that would make the five-year zero-growth estimate equal today’s price. This keeps the existing model inputs and calculation unchanged; it is an expectations lens, not a forecast.

This zero-growth estimate assumes trailing owner earnings persist — unreliable for declining businesses. The recent FY revenue series does not trigger the three-consecutive-declines flag.

Among the current top-score group, the median current price is 255% above the zero-growth estimate across 49 of the current top 50 companies by Moat Score with both values.

Score records captured Oct 16, 2026.

Exactly which 50 companies?

FTNT, IBEX, META, MEDP, MSFT, GOOG, LULU, ANF, IDXX, TXRH, FHI, QLYS, FFIV, ADBE, LLY, MANH, CPRT, VEEV, RMD, GRMN, PCTY, EAT, UI, SSD, MNST, DOCS, LRCX, MCO, NTAP, NVDA, CORT, SFM, MPTI, ULTA, SN, ROL, CTAS, PAYC, IRMD, DECK, MORN, INTU, JKHY, TPR, LGCY, DAL, GWW, ISRG, MPWR, LOPE

Missing a usable price or zero-growth estimate: ANF.

Model details under moat-index@3.0.0: zero-growth multiple 11.1×, capped-growth comparison at no more than 18×; 9% discount rate; high-end growth 0% (capped at 4%) using min(5y revenue CAGR, 5y diluted-EPS CAGR), clamped to 0%–4%; maintenance capex uses min(capex, D&A); abstain when D&A is unavailable. This is a disclosed model range, not intrinsic value as fact.

17 years of fundamentals

The business, in plain English

Alkermes plc. booked $1.5B of revenue in FY2025 in the Healthcare sector and kept 86.7% of it as gross profit — a high-margin business by that measure. After every other cost, 16.4% of each revenue dollar reached the bottom line.

Across the filed record, revenue grew from $178M (FY2010) to $1.5B (FY2025) — about 15.1% a year compounded over 15 years.

It earned 14.7% on invested capital in the latest filed year, FY2025. Across the full 16-year measurable filed record, median ROIC was −6.2%. Over the v3 recent window (10 measurable filed years), median ROIC was −3.5%. The Returns on Capital filter above scores it 11/100.

ALKS's latest filed year, FY2025, doesn't disclose total debt in a form the methodology can use, so current leverage is treated as unmeasured — never assumed to be zero.

Put together: Pricing Power is the strongest of the five filters (100/100) and Returns on Capital the weakest (11/100), which is how ALKS lands at 52/100 — a Shallow moat.

This breakdown is generated from the filed numbers and sub-scores above — no outside narrative, no estimates. Where a filing doesn’t disclose an input, the sentence that would need it is omitted instead of guessed.

Sales, as filed$1.5B FY2025

Revenue kept after cost of goods86.7% FY2025

Standard ROIC or separately labeled Operating ROICStandard ROIC 39.8% FY2023

Exact FY and FY-1 financing invested-capital inputs are required.

Cash an owner could take out$242M FY2025

The explained ROIC gaps have filed inputs but no meaningful positive invested-capital denominator. Other gaps mean the item is not in the filings for that year. The series is never interpolated or estimated. The Table view lists every filed value, including operating and net margins, total debt, and share count.

Flagship explainer

How Alkermes plc. makes its money

Start with a dollar of revenue and follow what the filing says remains.

Honest partial: the filing did not provide a normalized tag for Research and development, Selling, general and administrative; those components are omitted, not plugged.

Table alternative
Filed line	Value	% of revenue	Source
	$1.5B	100%	10-K · FY 2025Filing detailsAccession 0001193125-26-068925 · filed Feb 25, 2026
Cost of revenue	$196M	13%	10-K · FY 2025Filing detailsAccession 0001193125-26-068925 · filed Feb 25, 2026
	$1.3B	87%	10-K · FY 2025Filing detailsAccession 0001193125-26-068925 · filed Feb 25, 2026
	$254M	17%	10-K · FY 2025Filing detailsAccession 0001193125-26-068925 · filed Feb 25, 2026
Income before tax	$291M	20%	10-K · FY 2025Filing detailsAccession 0001193125-26-068925 · filed Feb 25, 2026
Income tax	$49.8M	3%	10-K · FY 2025Filing detailsAccession 0001193125-26-068925 · filed Feb 25, 2026
	$242M	16%	10-K · FY 2025Filing detailsAccession 0001193125-26-068925 · filed Feb 25, 2026

Source:

10-K · FY 2025Filing detailsAccession 0001193125-26-068925 · filed Feb 25, 2026

· event Dec 31, 2025 · retrieved Oct 16, 2026 · annual-row source set

Embed this chart

Flagship explainer

What Alkermes plc. owns — and owes

Alkermes plc.'s filing tags don't support a full breakdown — here's what is filed:

Table alternative
Filed line	Value	% of assets	Source
Total assets	$2.5B	100%	10-K · FY 2025Filing detailsAccession 0001193125-26-068925 · filed Feb 25, 2026
Cash and equivalents	$389M	16%	10-K · FY 2025Filing detailsAccession 0001193125-26-068925 · filed Feb 25, 2026
Stockholders’ equity	$1.8B	73%	10-K · FY 2025Filing detailsAccession 0001193125-26-068925 · filed Feb 25, 2026

Source:

10-K · FY 2025Filing detailsAccession 0001193125-26-068925 · filed Feb 25, 2026

· event Dec 31, 2025 · retrieved Oct 16, 2026 · annual-row source set

Flagship explainer

What drives Alkermes plc.’s return on equity?

ROE is five filed business factors multiplied together.

DuPont source inputs
Input	Value	Fiscal year	Source
	$242M	FY2025	10-K · FY 2025Filing detailsAccession 0001193125-26-068925 · filed Feb 25, 2026
Income before tax	$291M	FY2025	10-K · FY 2025Filing detailsAccession 0001193125-26-068925 · filed Feb 25, 2026
Operating income	$254M	FY2025	10-K · FY 2025Filing detailsAccession 0001193125-26-068925 · filed Feb 25, 2026
	$1.5B	FY2025	10-K · FY 2025Filing detailsAccession 0001193125-26-068925 · filed Feb 25, 2026
Ending assets	$2.5B	FY2025	10-K · FY 2025Filing detailsAccession 0001193125-26-068925 · filed Feb 25, 2026
Beginning assets	$2.1B	FY2024	10-K · FY 2024Filing detailsAccession 0001193125-26-068925 · filed Feb 25, 2026
	$1.8B	FY2025	10-K · FY 2025Filing detailsAccession 0001193125-26-068925 · filed Feb 25, 2026
	$1.5B	FY2024	10-K · FY 2024Filing detailsAccession 0001193125-26-068925 · filed Feb 25, 2026

Source:

10-K · filed Feb 25, 2026Filing detailsAccession 0001193125-26-068925 · filed Feb 25, 2026

· event Dec 31, 2025 · retrieved Oct 16, 2026 · annual-row source set

Embed this chart

Flagship explainer

Where Alkermes plc.'s cash went

Alkermes plc.’s filing does not supply enough provenance-matched cash-flow lines for a truthful flow chart — here’s what is filed:

Table alternative
Filed line	Value	% of cash from operations	Source
Cash from operations	$521M	100%	10-K · FY 2025Filing detailsAccession 0001193125-26-068925 · filed Feb 25, 2026
Depreciation and amortization	$27.2M	5%	10-K · FY 2025Filing detailsAccession 0001193125-26-068925 · filed Feb 25, 2026

Source:

10-K · FY 2025Filing detailsAccession 0001193125-26-068925 · filed Feb 25, 2026

· event Dec 31, 2025 · retrieved Oct 16, 2026 · annual-row source set

Curated 19-manager tier

Who reported holding Alkermes plc.

Delayed public 13F reports for 2026-Q2—not live positions, trades, or recommendations.

0 holding0 exited0 not holding0/19 resolved19 not retrieved

Named manager positions and quarter-over-quarter changes
Manager	Reported position	Quarter-over-quarter	Filing accession
Abrams Capital	Not retrieved	Comparison not retrieved	Filing not retrieved
Akre Capital	Not retrieved	Comparison not retrieved	Filing not retrieved
Baupost Group	Not retrieved	Comparison not retrieved	Filing not retrieved
Berkshire Hathaway	Not retrieved	Comparison not retrieved	Filing not retrieved
Brave Warrior Advisors	Not retrieved	Comparison not retrieved	Filing not retrieved
Dodge & Cox	Not retrieved	Comparison not retrieved	Filing not retrieved
First Eagle	Not retrieved	Comparison not retrieved	Filing not retrieved
Fundsmith	Not retrieved	Comparison not retrieved	Filing not retrieved
Gardner Russo & Quinn	Not retrieved	Comparison not retrieved	Filing not retrieved
Gates Foundation Trust	Not retrieved	Comparison not retrieved	Filing not retrieved
Mairs & Power	Not retrieved	Comparison not retrieved	Filing not retrieved
Markel / Markel-Gayner	Not retrieved	Comparison not retrieved	Filing not retrieved
Oakmark / Harris Associates	Not retrieved	Comparison not retrieved	Filing not retrieved
Pershing Square	Not retrieved	Comparison not retrieved	Filing not retrieved
Polen Capital	Not retrieved	Comparison not retrieved	Filing not retrieved
Sequoia / Ruane Cunniff	Not retrieved	Comparison not retrieved	Filing not retrieved
Southeastern Asset Management	Not retrieved	Comparison not retrieved	Filing not retrieved
Tweedy, Browne	Not retrieved	Comparison not retrieved	Filing not retrieved
Yacktman Asset Management	Not retrieved	Comparison not retrieved	Filing not retrieved

Position size uses shares and filed value from each manager’s 13F. Portfolio weight uses the eligible long-share filing denominator. Changes compare only with the immediately preceding calendar quarter.

Source: Filing source not retrieved · event Jun 30, 2026 · retrieved Oct 16, 2026

Flagship explainer

What Alkermes plc. insiders reported

Records still being gathered — partial as of retrieval Oct 16, 2026.

Partial coverage: the incomplete Form 4 walk cannot establish no activity, an activity date, or zero counts.

Moat Score history

Moat Score over timeLast scored reading of each day, on the 0–100 scale52.3 / 100

Breaks in the line mark methodology or normalizer upgrades — readings across versions aren’t compared, so a level shift there isn’t a change in the business.

Tier changesSame-methodology and same-normalizer crossings of the Wide / Narrow / Shallow bars

Normalizer upgraded unstamped (version unknown)tomoat-xbrl-normalizer@1.1.0 — readings across versions aren’t comparedJul 26, 2026
Methodology upgraded moat-index@2.0.0tomoat-index@3.0.0 — readings across versions aren’t comparedJul 23, 2026
Methodology upgraded moat-index@1.2.0tomoat-index@2.0.0 — readings across versions aren’t comparedJul 20, 2026

Scores are logged append-only and never overwritten — this record cannot be reconstructed retroactively, which is exactly why it’s worth keeping.

Insider activity

Form 4 reports mix P/S market or private transactions with compensation-plan mechanics. Activity casually described as “insider selling” can include compensation mechanics; awards, tax withholding, and option exercises are shown by their exact filed class here, never collapsed into “Bought” or “Sold.”

These are disclosed filing facts and arithmetic aggregates, not a signal or verdict.

This machine-readable surface covers SEC ownership filings from 2003; it does not represent earlier paper-era records.

Records still being gathered — partial as of retrieval Oct 16, 2026.

Among the rows shown, A/F/M acquisition, payment or withholding, and exercise or conversion rows outnumber S sale rows (17 versus 8). The filing codes alone do not establish that every such row arose from a compensation plan.

Trailing-12-month totals and the 90-day cluster result are withheld because this issuer walk is incomplete.

Insider					Shares owned after	Date	Filing detail
Reed JoshuaSVP, Chief Financial Officer	Exercise or conversion of derivative security (M)Table I · Acquired · Ordinary Shares · 1 paired event	9,164	Not disclosed	Not disclosed	9,164	Oct 8, 2026	1 filed lot Table I · Ordinary Shares: 9,164 shares at Not disclosed · code M · owned after 9,164 · Paired event: 9,164 Restricted Stock Unit Award → 9,164 Ordinary Shares · FORM 4 · filed Oct 9, 2026Filing detailsAccession 0001520262-26-000131 · filed Oct 9, 2026
Reed JoshuaSVP, Chief Financial Officer	Payment of exercise price or tax liability (F)Table I · Disposed · Ordinary Shares	4,069	$40.11	$163,208	5,095	Oct 8, 2026	1 filed lot Table I · Ordinary Shares: 4,069 shares at $40.11 · code F · owned after 5,095 · FORM 4 · filed Oct 9, 2026Filing detailsAccession 0001520262-26-000131 · filed Oct 9, 2026
Reed JoshuaSVP, Chief Financial Officer	Exercise or conversion of derivative security (M)Table II · Disposed · Restricted Stock Unit Award · 1 paired event	9,164	Not disclosed	Not disclosed	27,492	Oct 8, 2026	1 filed lot Table II · Restricted Stock Unit Award: 9,164 shares at Not disclosed · code M · owned after 27,492 · Paired event: 9,164 Restricted Stock Unit Award → 9,164 Ordinary Shares · FORM 4 · filed Oct 9, 2026Filing detailsAccession 0001520262-26-000131 · filed Oct 9, 2026
Whitaker Anne ClemDirector	Grant, award, or other acquisition (A)Table II · Acquired · Restricted Stock Unit Award	7,239	—Grant, award, or other acquisition (A)	—	7,239	Oct 7, 2026	1 filed lot Table II · Restricted Stock Unit Award: 7,239 shares at — (Grant, award, or other acquisition (A)) · code A · owned after 7,239 · FORM 4 · filed Oct 9, 2026Filing detailsAccession 0001520262-26-000130 · filed Oct 9, 2026
Whitaker Anne ClemDirector	Grant, award, or other acquisition (A)Table II · Acquired · Non Qualified Stock Option (Right to Buy)	17,998	—Grant, award, or other acquisition (A)	—	17,998	Oct 7, 2026	1 filed lot Table II · Non Qualified Stock Option (Right to Buy): 17,998 shares at — (Grant, award, or other acquisition (A)) · code A · owned after 17,998 · FORM 4 · filed Oct 9, 2026Filing detailsAccession 0001520262-26-000130 · filed Oct 9, 2026
Gaffin David JosephEVP, CLO, Alkermes, Inc.	Open-market or private sale (S)Table I · Disposed · Ordinary Shares	2,034	$41.03	$83,455	221,388	Oct 2, 2026	1 filed lot Table I · Ordinary Shares: 2,034 shares at $41.03 · code S · owned after 221,388 · FORM 4 · filed Oct 2, 2026Filing detailsAccession 0001520262-26-000127 · filed Oct 2, 2026
Gaffin David JosephEVP, CLO, Alkermes, Inc.	Open-market or private sale (S)Table I · Disposed · Ordinary Shares	2,034	$48.01	$97,652	223,422	Sep 3, 2026	1 filed lot Table I · Ordinary Shares: 2,034 shares at $48.01 · code S · owned after 223,422 · FORM 4 · filed Sep 3, 2026Filing detailsAccession 0001520262-26-000120 · filed Sep 3, 2026
Hopkinson Craig C.EVP R&D, Chief Medical Officer	Exercise or conversion of derivative security (M)Table I · Acquired · Ordinary Shares · 1 paired event	5,000	$24.59	$122,950	74,389	Sep 1, 2026	1 filed lot Table I · Ordinary Shares: 5,000 shares at $24.59 · code M · owned after 74,389 · Paired event: 5,000 Employee Stock Option (Right to Buy) → 5,000 Ordinary Shares · FORM 4 · filed Sep 1, 2026Filing detailsAccession 0001520262-26-000118 · filed Sep 1, 2026
Hopkinson Craig C.EVP R&D, Chief Medical Officer	Open-market or private sale (S)Table I · Disposed · Ordinary Shares	9,000	$46.986	$422,874	65,389	Sep 1, 2026	1 filed lot Table I · Ordinary Shares: 9,000 shares at $46.986 · code S · owned after 65,389 · FORM 4 · filed Sep 1, 2026Filing detailsAccession 0001520262-26-000118 · filed Sep 1, 2026
Hopkinson Craig C.EVP R&D, Chief Medical Officer	Exercise or conversion of derivative security (M)Table II · Disposed · Employee Stock Option (Right to Buy) · 1 paired event	5,000	—Exercise or conversion of derivative security (M)	—	61,276	Sep 1, 2026	1 filed lot Table II · Employee Stock Option (Right to Buy): 5,000 shares at — (Exercise or conversion of derivative security (M)) · code M · owned after 61,276 · Paired event: 5,000 Employee Stock Option (Right to Buy) → 5,000 Ordinary Shares · FORM 4 · filed Sep 1, 2026Filing detailsAccession 0001520262-26-000118 · filed Sep 1, 2026
Nichols Christian ToddSVP, Chief Commercial Officer	Open-market or private sale (S)Table I · Disposed · Ordinary Shares	7,576	$49.2261	$372,937	See lot detail	Aug 17, 2026	2 filed lots Table I · Ordinary Shares: 6,912 shares at $49.1851 · code S · owned after 102,857 · FORM 4 · filed Aug 17, 2026Filing detailsAccession 0001520262-26-000116 · filed Aug 17, 2026 Table I · Ordinary Shares: 664 shares at $49.6526 · code S · owned after 102,193 · FORM 4 · filed Aug 17, 2026Filing detailsAccession 0001520262-26-000116 · filed Aug 17, 2026
Jackson Blair CurtisDirector, President & CEO, Alkermes plc	Grant, award, or other acquisition (A)Table II · Acquired · Employee Stock Option (Right to Buy)	217,534	—Grant, award, or other acquisition (A)	—	See lot detail	Aug 5, 2026	2 filed lots Table II · Employee Stock Option (Right to Buy): 93,229 shares at — (Grant, award, or other acquisition (A)) · code A · owned after 93,229 · FORM 4 · filed Aug 7, 2026Filing detailsAccession 0001520262-26-000113 · filed Aug 7, 2026 Table II · Employee Stock Option (Right to Buy): 124,305 shares at — (Grant, award, or other acquisition (A)) · code A · owned after 124,305 · FORM 4 · filed Aug 7, 2026Filing detailsAccession 0001520262-26-000113 · filed Aug 7, 2026
snyderman nancy lynn MDDirector	Exercise or conversion of derivative security (M)Table I · Acquired · Ordinary Shares · 2 paired events	44,472	$46.72	$2,077,732	See lot detail	Aug 3, 2026	2 filed lots Table I · Ordinary Shares: 27,948 shares at $46.72 · code M · owned after 43,343 · Paired event: 27,948 Non Qualified Stock Option (Right to Buy) → 27,948 Ordinary Shares · FORM 4 · filed Aug 3, 2026Filing detailsAccession 0001520262-26-000111 · filed Aug 3, 2026 Table I · Ordinary Shares: 16,524 shares at $46.72 · code M · owned after 59,867 · Paired event: 16,524 Non Qualified Stock Option (Right to Buy) → 16,524 Ordinary Shares · FORM 4 · filed Aug 3, 2026Filing detailsAccession 0001520262-26-000111 · filed Aug 3, 2026
snyderman nancy lynn MDDirector	Open-market or private sale (S)Table I · Disposed · Ordinary Shares	44,472	$50.348	$2,239,076	15,395	Aug 3, 2026	1 filed lot Table I · Ordinary Shares: 44,472 shares at $50.348 · code S · owned after 15,395 · FORM 4 · filed Aug 3, 2026Filing detailsAccession 0001520262-26-000111 · filed Aug 3, 2026
snyderman nancy lynn MDDirector	Exercise or conversion of derivative security (M)Table II · Disposed · Non Qualified Stock Option (Right to Buy) · 2 paired events	44,472	—Exercise or conversion of derivative security (M)	—	See lot detail	Aug 3, 2026	2 filed lots Table II · Non Qualified Stock Option (Right to Buy): 27,948 shares at — (Exercise or conversion of derivative security (M)) · code M · owned after 0 · Paired event: 27,948 Non Qualified Stock Option (Right to Buy) → 27,948 Ordinary Shares · FORM 4 · filed Aug 3, 2026Filing detailsAccession 0001520262-26-000111 · filed Aug 3, 2026 Table II · Non Qualified Stock Option (Right to Buy): 16,524 shares at — (Exercise or conversion of derivative security (M)) · code M · owned after 0 · Paired event: 16,524 Non Qualified Stock Option (Right to Buy) → 16,524 Ordinary Shares · FORM 4 · filed Aug 3, 2026Filing detailsAccession 0001520262-26-000111 · filed Aug 3, 2026
Hopkinson Craig C.EVP R&D, Chief Medical Officer	Exercise or conversion of derivative security (M)Table I · Acquired · Ordinary Shares · 2 paired events	5,000	$24.4808	$122,404	See lot detail	Aug 3, 2026	2 filed lots Table I · Ordinary Shares: 104 shares at $19.34 · code M · owned after 73,493 · Paired event: 104 Employee Stock Option (Right to Buy) → 104 Ordinary Shares · FORM 4 · filed Aug 3, 2026Filing detailsAccession 0001520262-26-000110 · filed Aug 3, 2026 Table I · Ordinary Shares: 4,896 shares at $24.59 · code M · owned after 78,389 · Paired event: 4,896 Employee Stock Option (Right to Buy) → 4,896 Ordinary Shares · FORM 4 · filed Aug 3, 2026Filing detailsAccession 0001520262-26-000110 · filed Aug 3, 2026
Hopkinson Craig C.EVP R&D, Chief Medical Officer	Open-market or private sale (S)Table I · Disposed · Ordinary Shares	9,000	$48.58	$437,220	69,389	Aug 3, 2026	1 filed lot Table I · Ordinary Shares: 9,000 shares at $48.58 · code S · owned after 69,389 · FORM 4 · filed Aug 3, 2026Filing detailsAccession 0001520262-26-000110 · filed Aug 3, 2026
Hopkinson Craig C.EVP R&D, Chief Medical Officer	Exercise or conversion of derivative security (M)Table II · Disposed · Employee Stock Option (Right to Buy) · 2 paired events	5,000	—Exercise or conversion of derivative security (M)	—	See lot detail	Aug 3, 2026	2 filed lots Table II · Employee Stock Option (Right to Buy): 104 shares at — (Exercise or conversion of derivative security (M)) · code M · owned after 1,252 · Paired event: 104 Employee Stock Option (Right to Buy) → 104 Ordinary Shares · FORM 4 · filed Aug 3, 2026Filing detailsAccession 0001520262-26-000110 · filed Aug 3, 2026 Table II · Employee Stock Option (Right to Buy): 4,896 shares at — (Exercise or conversion of derivative security (M)) · code M · owned after 66,276 · Paired event: 4,896 Employee Stock Option (Right to Buy) → 4,896 Ordinary Shares · FORM 4 · filed Aug 3, 2026Filing detailsAccession 0001520262-26-000110 · filed Aug 3, 2026
Gaffin David JosephEVP, CLO, Alkermes, Inc.	Open-market or private sale (S)Table I · Disposed · Ordinary Shares	2,034	$48.58	$98,812	225,456	Aug 3, 2026	1 filed lot Table I · Ordinary Shares: 2,034 shares at $48.58 · code S · owned after 225,456 · FORM 4 · filed Aug 3, 2026Filing detailsAccession 0001520262-26-000109 · filed Aug 3, 2026

Source-event as of Oct 8, 2026. Retrieved Oct 16, 2026.

Track record

How Alkermes plc.’s moat rated in each of the years we can reconstruct from its filings — scored only on what was knowable at the time — and what its price and returns did afterward. The score never saw a price; the two are joined only in hindsight, for education, not as a signal.

Point-in-time Moat Score (dot colored by tier)Indexed price (total-return (dividends reinvested))Rated Wide-moat that year

How to read this: each dot is what the engine would have scored ALKS on that December 31; the line below is its total-return price path (dividends reinvested) in the years since.

Two tracks, one timeline: the score has its own 0–100 scale (top), the price its own 100-based scale (bottom) — never a shared axis. The price path is a total-return (dividends reinvested) index built from the same data the forward returns use; gaps in the score line are years with no reconstructed rating (see the table for why). The Table view carries every value.

What followed, in the years it rated Wide

In the reconstructed history shown, ALKS did not rate Wide-moat in any year, so there is no wide-moat track record to report. That absence is itself the honest answer — we don’t manufacture a comparison where the rating never earned one.

Healthcare context

#162 of 708 scored Healthcare companies, ranked by Moat Score.

Nearest peers by Moat Score

#160TMDX TransMedics Group, Inc.52.7 out of 100, Shallow moatShallow moat
#161LDDD LONGDUODUO COMPANY LIMITED52.6 out of 100, Shallow moatShallow moat
#163MYO Myomo, Inc.52.2 out of 100, Shallow moatShallow moat
#164BTCY BIOTRICITY INC.52.1 out of 100, Shallow moatShallow moat

Compare ALKS with its nearest peers →All Healthcare companies on the Index →

Common questions about ALKS

Does Alkermes plc. have an economic moat?: Based on its FY2025 SEC filings, the Moat Index scores Alkermes plc. (ALKS) 52.3 out of 100 — a Shallow moat. The five questions behind that score begin at 20% each; if exactly one genuinely lacks data, the other four weights are renormalized and disclosed. revenue and EPS trend 52, pricing power 100, returns on capital 11, balance-sheet safety 73, capital allocation 27.
Is ALKS trading below the conservative owner-earnings estimate?: The value if growth stopped today — a zero-growth baseline — is $16.21 per share. It capitalizes normalized owner earnings at a 9% rate and assumes 0% growth. Versus a recent price of $40.10, that is 147% above value if growth stopped today. The model also publishes a capped-growth comparison, but the zero-growth estimate is the cautious baseline. It assumes trailing owner earnings persist and is unreliable for declining businesses. This is an educational estimate from primary SEC filings, not intrinsic value as a fact or investment advice.
How has ALKS's Moat Score changed over time?: The record logs 29 readings since Jul 17, 2026; the latest reads 52.3 out of 100 (shallow moat). No tier changes on record yet. (Methodology or normalizer upgrades on Jul 20, 2026, Jul 23, 2026, Jul 26, 2026 re-based the score; readings across versions aren't compared.) The history is append-only — readings are only ever added, never rewritten.

Scored from primary SEC filings via the public methodology. Educational only — not a recommendation to buy or sell ALKS. See the disclaimer.